Evidence by area

Peptides and inflammation:
what studies measured

If you searched for “peptides for inflammation”, start with the model each study used. Five peptides have published work in inflammation-related settings: BPC-157, KPV, thymosin alpha 1, LL-37 and GHK-Cu. For each: what was measured, in cells, animals or people, and what is still unknown.

Short answerCompound research · 9 min read · Updated 21 Nov 2026

Thymosin alpha 1 and LL-37 have randomised trials in people. GHK-Cu has randomised trials on skin wounds, and the one that tracked redness found no difference on objective measures. BPC-157’s placebo-controlled trial with an inflammation-related measure is known only from a conference abstract that FDA staff judged inadequate, and we found no human study of KPV (November 2026). None of the five is an FDA-approved medicine; Italy authorises one medicine containing thymosin alpha 1.

Key takeaways

  • Thymosin alpha 1 has been tested against placebo in people: in a 2025 trial of 1,106 adults with sepsis, deaths within 28 days did not differ significantly, and FDA’s 2024 review found a lack of evidence of effectiveness for the uses it examined.
  • LL-37 is a peptide the body makes. In a 25-person ulcer trial, two inflammatory markers did not fall with LL-37 cream, and research on psoriasis and rosacea describes LL-37 as driving inflammation.
  • BPC-157’s placebo-controlled trial with an inflammation-related measure is known only from a 2005 conference abstract, which FDA staff judged inadequate to support efficacy or safety; an uncontrolled study that measured blood markers of inflammation has posted no results.
  • The inflammation-model studies of KPV and GHK-Cu used mice, zebrafish larvae and cells. We found no published human study or registered trial of KPV (21 November 2026). GHK-Cu has randomised trials on skin wounds; the one we found that tracked redness, after laser resurfacing, found no significant difference in how soon it resolved on objective measures.
  • None of the five is an FDA-approved medicine. Italy’s medicines agency lists one medicine containing thymosin alpha 1, Zadaxin, as authorised and prescription-only; research-grade material labelled thymosin alpha 1 is not that medicine.

01How far has research on peptides and inflammation gone?

How far the published research has gone for each peptide, dated 21 November 2026. Each bar shows the strongest type of study that gave the peptide in a setting marked by inflammation or infection. A longer bar means a stronger study design, not a better result. Bar lengths show order only; they are not a score.

Thymosin alpha 1
Trials
LL-37
Small trials
GHK-Cu
Trials
BPC-157
Abstract only
KPV
Mice, cells

Thymosin alpha 1: a placebo-controlled trial in 1,106 adults with sepsis. LL-37: randomised trials in people with chronic ulcers, the three described here with 25, 34 and 148 people. GHK-Cu: randomised trials on skin wounds, among them a skin-care trial after laser resurfacing that 13 people completed, plus mouse, zebrafish and cell models. BPC-157: one placebo-controlled trial known only from a conference abstract, plus rat models. KPV: mouse and cell models; we found no human study.

Source: the studies listed in the next section; FDA reviews of 2024 and 2026; searches of 21 Nov 2026.

Is any of them an approved medicine? Not in the US. FDA’s reviews state that BPC-157, KPV and thymosin alpha 1 are not components of any FDA-approved drug, and Drugs@FDA lists no product containing LL-37 or GHK-Cu (searched 21 November 2026). Thymosin alpha 1 is the exception abroad. Italy’s medicines agency lists Zadaxin (timosina alfa 1) as authorised and prescription-only, and FDA’s 2024 review describes that authorisation as “an adjuvant to influenza vaccination in immunocompromised individuals”. The same review records approval in India, for chronic hepatitis B in adults with compensated liver disease, and in Hong Kong. Research-grade material labelled thymosin alpha 1 is not any of those medicines.

02What did each study measure, and in which model?

Each peptide, the strongest study we found in an inflammation-related setting, and what that study cannot tell you. Dated 21 November 2026. Tiers follow our evidence grades; sources are at the end of the page.

PeptideWhat it isStrongest study in an inflammation-related settingWhat was measuredTierWhat we don’t know
Thymosin alpha 1 (thymalfasin)A 28-amino-acid peptide that FDA describes as physiologically present in the human body; thymalfasin is the synthetic versionTESTS, 2025: phase 3, double-blind, placebo-controlled; 1,106 adults with sepsis at 22 centres in ChinaDeath from any cause within 28 daysT1Any effect in healthy people: the trials described here enrolled people with sepsis or chronic hepatitis B
LL-37A 37-amino-acid peptide the body makes, cut from a 170-amino-acid precursor protein, cathelicidinMahlapuu et al., 2021: phase IIb, randomised, double-blind; 148 adults with hard-to-heal venous leg ulcers. Miranda et al., 2023: randomised, double-blind; 25 adults with mildly infected diabetic foot ulcersUlcer closure measures (2021); two inflammatory markers and bacteria in wound fluid, and a wound granulation index (2023)T1, smallWhich way LL-37 moves inflammation: in the 2023 trial the two markers did not fall, and other research describes LL-37 as driving inflammation
GHK-CuA three-amino-acid peptide, glycyl-histidyl-lysine, bound to copperMulder et al., 1994: multicentre, randomised, evaluator-blinded, placebo-controlled trial of a GHK-Cu gel on chronic skin wounds. Miller et al., 2006: randomised; skin-care regimens with or without GHK-Cu after laser resurfacing around the mouth; 13 people completed itWound closure and wound infections (1994); redness after the laser, by computer analysis and blinded evaluators (2006)T1; T3 and T4 for the disease modelsAny effect on inflammation in people: the 2006 trial found no significant difference in how soon redness resolved on objective measures, the 1994 abstract reports no inflammation measure, and the disease-model studies used animals and cells
BPC-157A synthetic peptide of 15 amino acidsRuenzi et al., 2005, a conference abstract: multicentre, randomised, double-blind, placebo-controlled; 53 patients, 46 completedA disease-activity score that the abstract did not clearly defineT1 by design; known only from an abstractWhether it changes inflammation in people: FDA staff found the abstract’s data inadequate to support efficacy or safety
KPVA three-amino-acid peptide, lysine–proline–valineDalmasso et al., 2008: mice with two chemically induced forms of colitis, and human cell lines. Kannengiesser et al., 2008: mice with two forms of experimental colitisColon tissue under the microscope, cytokine gene activity, body weight and myeloperoxidase activity; inflammatory signalling in cellsT3, T4Any effect in people: we found no published human study or registered trial (21 Nov 2026)

03Which peptides were tested in which models?

Three groups, by the length of the chain. In the drawings, each bead is one amino acid.

Cu
Models: mice, zebrafish, cells

KPV and GHK-Cu

Two peptides of three amino acids each; GHK-Cu also carries a copper ion. Their inflammation-model studies used mice, zebrafish larvae and cells. GHK-Cu also has randomised trials on skin wounds; we found no human study of KPV.

Rats · one abstract-only trial

BPC-157

A synthetic peptide of 15 amino acids. Its gut studies used rats; one placebo-controlled trial in people is known only from a conference abstract.

Randomised trials in people

Thymosin alpha 1 and LL-37

Chains of 28 and 37 amino acids. Both have been tested against placebo in people: in sepsis, chronic hepatitis B and chronic ulcers.

More on each: thymosin alpha 1, LL-37, BPC-157, GHK-Cu and KPV.

04What have studies in people measured?

Four of the five have been given to people in a study with an inflammation-related measure or setting. We report what each study measured and whether it met its main goal.

Thymosin alpha 1: deaths in sepsis (T1, n=1,106). The TESTS trial randomised 1,106 adults with sepsis at 22 centres in China between 2016 and 2020 and analysed 1,089. Death from any cause within 28 days occurred in 23.4% of the thymosin alpha 1 group and 24.1% of the placebo group (hazard ratio 0.97, 95% CI 0.76 to 1.24, as corrected in May 2025). The authors found “no clear evidence” that it lowered 28-day mortality, and no secondary or safety outcome differed significantly. The trial’s declared support included SciClone Pharmaceuticals; Italy’s medicines agency lists a SciClone company as the holder of Zadaxin’s authorisation. An older placebo-controlled trial in 97 adults with chronic hepatitis B (1999) did not reach statistical significance on its main measure (14% versus 4%, P=0.084).

What FDA concluded about thymosin alpha 1. FDA’s 2024 review of its proposed uses, sepsis among them, concluded that there is “a lack of evidence to support the effectiveness” for all of them; that review predates the TESTS paper. On safety, the review says that in most clinical studies it “has been found to be well-tolerated”, and also that its use in compounding “may raise safety concerns”, because as a 28-amino-acid peptide given by injection it “may pose a significant risk for immunogenicity”, an immune reaction against the peptide itself.

LL-37: ulcer trials (T1, small). LL-37 has been applied to chronic ulcers in randomised trials, and company scientists are among the authors of the first two. In a 2014 trial in 34 adults with hard-to-heal venous leg ulcers, healing-rate measures were higher than placebo at the two lower strengths tested, significantly so only at the lowest, and no different at the highest. In the largest described here, a phase IIb trial of 148 adults (2021), the analysis of all patients “did not identify any significant improvement in healing” compared with placebo; its authors reported better results in a subgroup with large ulcers, chosen after the fact. A 2023 trial in 25 adults with mildly infected diabetic foot ulcers measured two inflammatory markers, IL-1α and TNF-α, in wound fluid. The markers rose in both groups, and LL-37 cream did not lower them compared with placebo cream; a wound granulation index rose more with LL-37. FDA’s compounding page says the agency “lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans”, and adds: “Nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues.” Protumorigenic means able to promote tumour growth.

LL-37 on the other side of inflammation (T2, T3, T4). In 2007, researchers working with psoriatic skin and human immune cells reported that LL-37 binds the body’s own DNA into structures that set off interferon release, and called it “the key factor” in that activation. The same year, another group found “abnormally high levels of cathelicidin” in the facial skin of people with rosacea, and reported that putting those cathelicidin fragments into mouse skin increased inflammation. In these studies LL-37 drives inflammation. They are mechanism studies in samples, cells and mice, not tests of giving LL-37 to people.

BPC-157: one abstract and one unpublished study. Reviewing BPC-157 in 2026, FDA staff found a single meeting abstract of a multicentre, randomised, double-blind, placebo-controlled study in 53 people with mild to moderate ulcerative colitis, of whom 46 completed it. Its primary measure was a disease-activity score that the abstract did not clearly define. Because key details were missing, FDA staff concluded that the data “are therefore inadequate to support the efficacy and safety” of BPC-157 in that setting. A second study is registered. NCT07752381 gave a commercial product containing BPC-157, made by the study’s sponsor, to 40 physically active adults with no control group. Its primary measures are two blood markers of inflammation, hs-CRP and IL-6, and self-reported swelling. It was completed in November 2025, has posted no results, and we found no publication (ClinicalTrials.gov and PubMed, 21 November 2026). FDA staff also found “insufficient clinical safety information to characterize the safety profile” of BPC-157, and wrote that as a peptide “administered through a parenteral or nasal” route it “may pose a significant risk for immunogenicity”. More: BPC-157 human studies.

GHK-Cu: trials on skin wounds (T1). A 1994 multicentre, randomised, evaluator-blinded, placebo-controlled trial applied a GHK-Cu gel to foot ulcers in people with diabetes, alongside standard wound care, and measured wound closure and ulcer infections; its abstract reports no inflammation measure. The randomised trial we found that tracked redness, a sign of inflammation (21 November 2026), randomised people having laser resurfacing around the mouth to skin-care regimens with or without GHK-Cu; 13 completed it. It tracked redness by computer analysis and blinded evaluators, and assessed wrinkles, skin appearance and a patient questionnaire at 12 weeks. On objective measures it found no statistically significant difference between groups: not in how soon redness resolved, and not in evaluators’ ratings of wrinkles or skin quality.

05What have animal and cell studies measured?

KPV, BPC-157 and GHK-Cu have inflammation-model studies in rodents, zebrafish and cells. We describe the models and what was measured, not the authors’ findings. Animal and cell results are not evidence of an effect in people.

KPV (T3, T4). In 2008, researchers at Emory University exposed two human intestinal cell lines and a human T-cell line to inflammatory signals, with and without KPV, and gave KPV to mice with two chemically induced forms of colitis. They measured inflammatory signalling in the cells, the cytokines the cells released, and inflammation in the mouse colon under the microscope and by cytokine gene activity. The same year, a group at the University of Münster gave KPV to mice with chemically induced colitis and to mice whose colitis was set off by transferred immune cells, and tracked body weight, colon tissue under the microscope and myeloperoxidase activity in colon tissue. FDA staff wrote in 2026 that the molecular targets of KPV “remain unknown”. They found no clinical studies or human exposure data by any route, and concluded that “potential safety risks associated with the use of KPV in humans are unknown”. HHS read the record differently: its 2026 policy appendix says KPV’s “historical use is now documented and quantified”, and that the safety conclusion of FDA’s drug centre “reflects an absence of information rather than an observed signal”. Use is not a study.

BPC-157 (T3). The gut studies are in rats, and the two cited here come from one research group at the University of Zagreb. A 2013 study used rats given cysteamine to induce colitis and rats with a surgical join in the colon, examined between days 3 and 14. A 2017 study tied off the blood supply to a segment of rat colon and recorded how the blood vessels filled, along with tissue levels of a marker of oxidative stress and of nitric oxide. FDA’s 2026 review describes further rat models, including surgically made fistulas whose size was assessed by eye. FDA staff cautioned that these studies had not established how effects change with the amount given, that BPC-157’s molecular targets “have not been identified” and that its mechanisms of action “remain poorly understood”.

GHK-Cu (T3, T4). The disease-model studies we found gave GHK-Cu to mice whose lungs had been inflamed by a bacterial toxin (2016), cigarette smoke (2022), an allergen (2023) or silica dust (2024), and to mice with chemically induced colitis (2025). A 2026 study used zebrafish larvae. They measured cytokines such as TNF-α and IL-6, inflammatory cells in tissue and tissue changes under the microscope. A 2012 cell study measured IL-6 released by human skin fibroblasts. Gut research in context: KPV and BPC-157 gut studies.

06What has not been shown about peptides and inflammation?

An effect on inflammation in healthy people

The published human studies above enrolled people with sepsis, chronic hepatitis B, chronic ulcers or colitis, or people having a laser procedure. The one study in physically active adults had no control group and has posted no results.

That animal and cell findings carry over to people

We found no human study of KPV (PubMed and ClinicalTrials.gov, 21 Nov 2026). The disease-model studies of GHK-Cu and BPC-157 used rodents, zebrafish and cells.

Which way LL-37 moves inflammation

In a 25-person ulcer trial, two inflammatory markers did not fall with LL-37. In psoriasis and rosacea research, LL-37 is described as driving inflammation.

Whether they cause harm in people

FDA’s compounding page (current as of 22 April 2026) says the agency lacks the information to know whether BPC-157, KPV or LL-37 would cause harm when given to humans.

How these tiers are assigned: evidence grades. Why we publish no amounts for any compound: our policy.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not medical or legal advice.

RefSources

  1. U.S. Food and Drug Administration. FDA evaluation of thymosin alpha-1 (Ta1)-related bulk drug substances, briefing document for the Pharmacy Compounding Advisory Committee meeting of 4 December 2024. Advisory committee briefing, dated 15 Nov 2024 (pp. 12, 15, 26, 42–43, 79, 121, 125); read 21 Nov 2026. www.fda.gov/media/183820/download
  2. Wu J, Pei F, Zhou L, et al. [TESTS: multicentre, double-blind, randomised, placebo-controlled phase 3 trial of thymosin α1 in 1,106 adults with sepsis.] BMJ, 2025;388:e082583. PMID 39814420. Figures on this page are as corrected on 30 May 2025 (BMJ 2025;389:r1098, PMID 40447307; correction read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/39814420/
  3. Mutchnick MG, Lindsay KL, Schiff ER, et al. [Phase III, multicentre, randomised, double-blind, placebo-controlled trial of thymosin alpha 1 in 97 adults with chronic hepatitis B.] J Viral Hepat, 1999;6(5):397–403. PMID 10607256 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/10607256/
  4. Agenzia Italiana del Farmaco (AIFA). Banca dati farmaci: Zadaxin (timosina alfa 1), holder SciClone Pharmaceuticals Italy S.r.l., authorised, prescription-only. Italian medicines database record, read through AIFA’s public data service on 21 Nov 2026. medicinali.aifa.gov.it/it/#/it/dettaglio/0000022315
  5. Mahlapuu M, Sidorowicz A, Mikosinski J, et al. [HEAL LL-37: phase IIb, randomised, double-blind, placebo-controlled trial of LL-37 in 148 adults with venous leg ulcers; authors from Promore Pharma, which is developing it.] Wound Repair Regen, 2021;29(6):938–950. PMID 34687253 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/34687253/
  6. Grönberg A, Mahlapuu M, Ståhle M, et al. [Randomised, placebo-controlled trial of LL-37 at three strengths in 34 adults with venous leg ulcers; first author at Pergamum AB.] Wound Repair Regen, 2014;22(5):613–621. PMID 25041740 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/25041740/
  7. Miranda E, Bramono K, Yunir E, et al. [Randomised, double-blind trial of LL-37 cream or placebo cream in 25 adults with diabetic foot ulcers.] Arch Dermatol Res, 2023;315(9):2623–2633. PMID 37480520 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/37480520/
  8. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007;449(7162):564–569. PMID 17873860. Yamasaki K, Di Nardo A, Bardan A, et al. [Cathelicidin and protease activity in the facial skin of people with rosacea, and in mice.] Nat Med, 2007;13(8):975–980. PMID 17676051 (abstracts read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/17873860/
  9. UniProt. P49913, cathelicidin antimicrobial peptide (human): 170-amino-acid precursor; antibacterial peptide LL-37 at residues 134–170. Protein database entry, version 199; read 21 Nov 2026. www.uniprot.org/uniprotkb/P49913/entry
  10. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  11. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 9, 27, 31–32, 43–44, 46); read 21 Nov 2026. www.fda.gov/media/193343/download
  12. ClinicalTrials.gov. NCT07752381: single-group study of a commercial product containing BPC-157 in 40 physically active adults. Registry record, first posted 7 Aug 2026; read 21 Nov 2026 (completed; no results posted). clinicaltrials.gov/study/NCT07752381
  13. Klicek R, Kolenc D, Suran J, et al. [Rat study of BPC 157 in cysteamine-induced colitis and a colon anastomosis.] J Physiol Pharmacol, 2013;64(5):597–612. PMID 24304574. Duzel A, Vlainic J, Antunovic M, et al. [Rat study of BPC 157 in a colon segment cut off from its blood supply.] World J Gastroenterol, 2017;23(48):8465–8488. PMID 29358856 (abstracts read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/?term=24304574+OR+29358856
  14. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: KPV-related bulk drug substances. Advisory committee briefing, 2026 (pp. 7, 25–27); read 21 Nov 2026. www.fda.gov/media/193346/download
  15. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix B. Policy document, 2026, undated in its text. hhs.gov returned 403 on 21 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest readable capture of the file (pp. 8–9). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  16. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. [Mouse colitis and cell study of KPV.] Gastroenterology, 2008;134(1):166–178. PMID 18061177. Kannengiesser K, Maaser C, Heidemann J, et al. [Mouse study of KPV in two models of colitis.] Inflamm Bowel Dis, 2008;14(3):324–331. PMID 18092346 (abstracts read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/?term=18061177+OR+18092346
  17. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/16847171/
  18. Mulder GD, Patt LM, Sanders L, et al. [Multicentre, randomised, evaluator-blinded, placebo-controlled trial of a glycyl-L-histidyl-L-lysine copper gel in people with diabetic foot ulcers.] Wound Repair Regen, 1994;2(4):259–269. PMID 17147644 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/17147644/
  19. Animal and cell studies of GHK-Cu in inflammation models, each cited by a neutral description: Park JR et al., Oncotarget 2016;7(36):58405–58417 (PMID 27517151; mice, lung injury from bacterial toxin); Zhang Q et al., Front Mol Biosci 2022;9:925700 (PMID 35936787; mice, cigarette smoke); Zhang Q et al., Biomed Pharmacother 2023;164:114936 (PMID 37257226; mice, allergen); Bian Y et al., Redox Biol 2024;75:103237 (PMID 38879894; mice, silica); Mao S et al., Front Pharmacol 2025;16:1551843 (PMID 40672369; mice, colitis); Hu J et al., Eur J Pharmacol 2026;1023:178880 (PMID 41997403; zebrafish larvae); Gruchlik A et al., Acta Pol Pharm 2012;69(6):1303–1306 (PMID 23285694; human skin fibroblasts). Abstracts read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=27517151+OR+35936787+OR+372572…
  20. Database searches run 21 Nov 2026: Drugs@FDA through openFDA (BPC-157, KPV, thymalfasin, thymosin, cathelicidin, prezatide, copper tripeptide, GHK: no match; control “semaglutide”: found); PubMed (KPV with clinical-trial and case-report publication types: none; GHK-Cu terms with clinical-trial publication types: one, PMID 16847171; glycyl-L-histidyl-L-lysine copper without a publication-type filter: PMID 17147644; NCT07752381: no publication); ClinicalTrials.gov (KPV as intervention: no record). Registry and database queries. clinicaltrials.gov/search?intr=KPV

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is any of these five peptides an approved medicine?

None is FDA-approved. Italy’s medicines agency lists one medicine containing thymosin alpha 1, Zadaxin, as authorised and prescription-only; research-grade material labelled thymosin alpha 1 is not that medicine.

What human studies of BPC-157 measured inflammation?

One placebo-controlled trial in 53 patients is known only from a 2005 conference abstract, and FDA staff found its data inadequate to support efficacy or safety. An uncontrolled study that measured blood markers of inflammation was completed in 2025 and has posted no results.

Has KPV been tested in people?

Not in any published study or registered trial we found (PubMed and ClinicalTrials.gov, 21 November 2026), and FDA found no human exposure data. HHS wrote in 2026 that its historical use is documented and quantified; that is use, not a study.

What did LL-37 studies measure on inflammation?

In a 25-person ulcer trial, two inflammatory markers in wound fluid did not fall with LL-37 cream compared with placebo cream. Research on psoriasis and rosacea describes LL-37 as driving inflammation.

What did the thymosin alpha 1 sepsis trial find?

In 1,106 adults with sepsis, deaths within 28 days were 23.4% with thymosin alpha 1 and 24.1% with placebo, not a significant difference (hazard ratio 0.97, 95% CI 0.76 to 1.24, as corrected in May 2025).

What did the GHK-Cu trial after laser resurfacing measure?

Redness after laser resurfacing, in a 2006 randomised trial that 13 people completed. On objective measures it found no statistically significant difference between regimens with and without GHK-Cu, including in how soon redness resolved.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page